Multiple myeloma trials in Germany

In Germany 64 Also abroad 703

64 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in Germany
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Where
Berlin, Dresden, Essen, Hamburg, Leipzig, Munich, Oldenburg
Age
18 years and over
People
249 worldwide
Run by
AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00
No phaseTaking people
Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)
Where
Munich
Age
18 years to 99 years
People
80
Run by
Technical University of Munich
See details and how to joinNCT07851493
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz, München, Nuremberg, Würzburg
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Freiburg im Breisgau, Hamburg, Tübingen
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 1/2Taking people
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Where
Heidelberg, Luebeck
Age
18 years and over
People
78 worldwide
Run by
Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00
Phase 3Not yet taking people in Germany
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Where
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Magdeburg, Mainz, Munich, Nuremberg, Wuerzburg
Age
18 years and over
People
234 worldwide
Run by
AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00
Phase 1/2Taking people
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Dresden, Hamburg, Heidelberg
Age
18 years and over
People
62 worldwide
Run by
Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, Würzburg
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
Phase 1Taking people
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Where
Dresden
Age
18 years and over
People
16
Run by
Technische Universität Dresden
See details and how to joinNCT05836896 · EU 2022-502831-20-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Where
Bamberg, Frankfurt, Hamburg, Hösbach, Karlsruhe, Koblenz, Munich
Age
18 years and over
People
200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Berlin, Brunswick, Chemnitz, Munich, Ulm, Wuerzburg
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Berlin, Bonn, Cottbus, Freiburg im Breisgau, Hamburg, Hamm, Jena, Nuremberg, Speyer, Stuttgart, Ulm
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
No phaseTaking people
Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders
Where
Munich, Regensburg, Würzburg
Age
18 years and over
People
51
Run by
Wuerzburg University Hospital
See details and how to joinNCT07040189
No phaseTaking people
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
Where
Augsburg, Erlangen, München, Regensburg, Würzburg
Age
18 years and over
People
198
Run by
Wuerzburg University Hospital
See details and how to joinNCT07649681
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Dresden, Hamburg, Munich, Oldenburg, Wuerzburg
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 1/2Taking people
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Where
Berlin, Essen, Heidelberg, Wuerzburg
Age
18 years and over
People
220 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig, Magdeburg, Mainz, München, Nuremberg, Würzburg
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 3Taking people
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
Where
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz, Nuremberg, Wuerzburg
Age
18 years and over
People
153 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523285-25-00 · EU 2025-523285-25-00
Phase 3Not yet taking people in Germany
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Bonn, Cologne, Freiburg im Breisgau, Hanover, Karlsruhe, Tübingen, Ulm, Würzburg
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Hamburg, Heidelberg, Munich, Wuerzburg
Age
18 years and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
No phaseTaking people
Myeloma Registry Platform (MYRIAM)
Where
Multiple Sites
Age
18 years and over
People
2,200
Run by
iOMEDICO AG
See details and how to joinNCT03308474
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Chemnitz
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
No phaseTaking people
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Where
Freiburg im Breisgau
Age
18 years and over
People
50
Run by
iOMEDICO AG
See details and how to joinNCT07559799
Phase 3Not yet taking people in Germany
GMMG-HD11/DSMM XXI/64007957MMY3010
Where
Aachen, Augsburg, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Chemnitz, Cottbus, Dessau-Rosslau, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Göttingen, Greifswald, Hagen, Hamburg, Hannover, Heidelberg, Heilbronn, Jena, Kaiserslautern, Karlsruhe, Kiel, Koblenz, Köln, Leipzig, Ludwigshafen Am Rhein, Magdeburg, Mainz, Mannheim, Marburg, Muenster, Munich, Nürnberg, Oldenburg, Osnabrueck, Potsdam, Regensburg, Schwaebisch Hall, Siegen, Stuttgart, Tuebingen, Ulm, Villingen-Schwenningen, Winnenden, Wuerzburg
Age
18 years to 70 years
People
399
Run by
University of Heidelberg Medical Center
See details and how to joinNCT07671287 · EU 2025-523990-40-00
Phase 1/2Not yet taking people in Germany
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Where
Hamburg
Age
18 years and over
People
220
Run by
Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT07600151 · EU 2025-523049-83-00